baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

IDORSIA LTD/ CH0363463438 /

5/17/2024 5:17:29 PM	Chg. -0.13	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
2.22CHF	-5.37%	15,508 Turnover: 34,221.87	-Bid Size: -	-Ask Size: -	-CHF	-	-

GlobeNewswire 5/9 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

GlobeNewswire 4/17 Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determ...

GlobeNewswire 4/1 Nxera Pharma is the New Name for Sosei Group

GlobeNewswire 3/27 Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of C...

GlobeNewswire 2/28 Idorsia and Viatris enter into a significant global research and development collaboration

GlobeNewswire 2/16 Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Offic...

GlobeNewswire 2/13 Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

GlobeNewswire 1/22 Sosei Heptares Webinar Presentation for FY2023 Financial Results

GlobeNewswire 1/5 Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief O...

GlobeNewswire 12/7/2023 Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

GlobeNewswire 11/15/2023 Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

GlobeNewswire 11/10/2023 Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...

GlobeNewswire 11/3/2023 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...

GlobeNewswire 10/31/2023 Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), ...

GlobeNewswire 10/25/2023 Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress

GlobeNewswire 10/16/2023 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 9/11/2023 Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Of...

GlobeNewswire 2/28/2022 Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

GlobeNewswire 2/17/2022 Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

GlobeNewswire 2/8/2022 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...

GlobeNewswire 2/3/2022 Nox Health Announces New Chief Marketing Officer, SVP of Content and VP of Security

GlobeNewswire 2/3/2022 Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

GlobeNewswire 1/26/2022 Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and ...

GlobeNewswire 1/18/2022 Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue

GlobeNewswire 1/11/2022 Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

IDORSIA LTD/ CH0363463438 /

If you wish to receive reply to your feedback, please provide your email address.